

UNITED STAKES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARK Washington, D.C. 20231


APPLICATION NUMBER FILING DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NO. 05/04/200 WALDMANN **EXAMINER** TON ART UNIT PAPER NUMBER **L32** 14 **DATE MAILED: INTERVIEW SUMMARY** All participants (applicant, applicant's representative, PTO personnel): MARK COHEN Type: Telephonic Televideo Conference Personal (copy is given to applicant personal (copy is given to applicant personal (copy is given to applicant personal personal (copy is given to applicant personal personal personal (copy is given to applicant personal perso Exhibit shown or demonstration conducted: Yes No If yes, brief description:_____ Agreement was reached. Was not reached. Claim(s) discussed: Identification of prior art discussed: NDNE Description of the general nature of what was agreed to if an agreement was reached, or any other comments:_ CLAIM AMENDMENTS AND EVIDENCE FOR ENABLEMENT. (A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.) It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary. A FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has are ready been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE

Examiner Note: You must sign this form unless it is an attachment to another form.

Deberal Cronch

SUBSTANCE OF THE INTERVIEW.



<u>Invention</u>: Methods for producing long-term cultures of immature dendritic cells by culturing ES cells.

Final Rejection:

Specification is objected to because they haven't submitted a copy of the spec with a marked up version.

112, 1st They are enabling for long-term culture of immature dendritic cells wherein they culture mouse ES cells from the mouse ES cell line ESF116 under appropriate conditions (see claims). We argued that the state of the art is such that ES cells are not available. Applicants argue that it is common knowledge that other ES cell lines derived from 129/SV mice (a different cell line) are capable of supporting esDC growth. We argued that the specification is not enabling as filed – that they provided post-filing art to show they are *now* enabled. The spec doesn't provide teaching for using any other cell line to produce long-term cultures of immature dendritic cells.